Open dataset · Orange Book Generic Competition · doi:10.5281/zenodo.24172675
Orange Book Generic Competition 2026: the open dataset behind the Generic Competition Check
A generic is listed as marketed
1,083 of 2,145 (50%)
No generic is listed as marketed
1,062 of 2,145 (50%)
What is in it?
The Orange Book's 48,865 product rows grouped by ingredient and dosage form (4,530 groups), with, for each group, the number of brand and generic products, how many are listed as marketed (not listed as discontinued), the number of distinct generic applicants, the first brand and first generic approval dates, and the patents and exclusivities still listed after the download date.
How should it be read?
"Marketed" means only that the Orange Book does not list a product as discontinued; it says nothing about stock, price or supply. A listed patent is the application holder's listing, not a ruling, and does not mean a generic is blocked.
What are the files?
The files are hosted on Zenodo with the DOI. Each has a SHA-256 hash, so a downloaded copy can be checked against it.
| File | Size | SHA-256 (first 16) |
|---|---|---|
| README.md | 2 KB | e4ce53badf1719bb |
| groups.csv | 390 KB | c7167e43ea1aed81 |
| products.csv | 6.2 MB | f9b2470bee4920bf |
| patents.csv | 1.6 MB | fe606adb0934d6dc |
| exclusivities.csv | 140 KB | 9e8f743928b76b1d |
| data.json | 790 bytes | 01daeb9d14530b7d |
| control-result.json | 332 bytes | 6ba7afb69a52c33b |
| PROTOCOL-GENERIC-COMPETITION-2026-11-12.md | 3 KB | 07cfc57c08db1305 |
| protocol.sha256 | 109 bytes | 66fa4c48c74e5411 |
| code.zip | 25 KB | 4d0cfa9ca6f8a6b6 |
| SHA256SUMS.txt | 902 bytes | |
- groups.csv: one row per ingredient and dosage-form group. products.csv, patents.csv, exclusivities.csv: the rows behind it. data.json: the headline counts.
- PROTOCOL-GENERIC-COMPETITION-2026-11-12.md and protocol.sha256: the method, frozen before any competition statistic was published.
- control-result.json: the independent control. code.zip: the scripts that built these files.
How was it checked?
The method was frozen before any figure was published, on 12 November 2026; its SHA-256 hash begins 07cfc57c08db1305. A separate reader recomputed figures from the raw files: a random sample of 400 recomputed, 0 mismatches. Read how the Generic Competition Check was checked, including what the check found and what it does not cover.
What is not claimed?
That a generic will launch or on what date; that fewer makers means a higher price or a shortage; anything about price, supply or quality. Biologics are not in the Orange Book.
Has it been corrected?
None yet. Control: 400 sampled groups, 0 mismatches (the applicant-name rule is shared, see control-result.json).
How do I cite it?
Couey, V. W. (2026). Orange Book Generic Competition 2026: Generic Makers, First Generic Approvals and Listed Patents for 2,760 Ingredients (Version 1.0) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.24172675
Cite all versions: doi:10.5281/zenodo.24172674. This version: doi:10.5281/zenodo.24172675.
Where does the data come from?
US Food and Drug Administration, Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), data files downloaded 2026-11-12. Compiled by Vincent Wesley Couey (ORCID 0009-0005-6869-308X). Tool: https://omnirx.org/tools/generic-competition-check
Questions about this dataset
What is in the Orange Book Generic Competition dataset?
The Orange Book's 48,865 product rows grouped by ingredient and dosage form (4,530 groups), with, for each group, the number of brand and generic products, how many are listed as marketed (not listed as discontinued), the number of distinct generic applicants, the first brand and first generic approval dates, and the patents and exclusivities still listed after the download date.
Can I reuse it?
Yes. The compilation is licensed CC BY 4.0: reuse it with credit, citing the DOI (10.5281/zenodo.24172675). The underlying records keep the terms of their public source.
How was it checked?
The method was frozen and hashed before any figure was published (12 November 2026), and a separate reader recomputed figures from the raw files: a random sample of 400 recomputed, 0 mismatches. The full account is on the how-we-check page for the tool.
What does it not claim?
That a generic will launch or on what date; that fewer makers means a higher price or a shortage; anything about price, supply or quality. Biologics are not in the Orange Book.
Compiled by Vincent Wesley Couey (ORCID 0009-0005-6869-308X).